Journal of Liver Cancer

Park, Joong Won

1 Article

Systemic Therapy for Advanced Hepatocellular Carcinoma: Targeted Therapy and Immunotherapy: Kim, Bo Hyun , Park, Joong Won; J Liver Cancer. 2018;18(1):17-22. Published online March 31, 2018; DOI: https://doi.org/10.17998/jlc.18.1.17

2,225 Views
75 Downloads
1 Citation

Systemic therapy for hepatocellular carcinoma (HCC) has markedly changed since 2007, with the approval of sorafenib. Sorafenib improved the overall survival of patients with advanced HCC; however, the modest efficacy and toxicity of this therapy present unmet needs. Subsequently, a variety of molecular targeted agents have been tested as first-line or secondline therapies but have failed, and sorafenib has remained the only approved systemic agent for almost 10 years. Recently, regorafenib significantly improved overall survival and was approved for patients with HCC who have been previously treated with sorafenib. Nivolumab, a programmed death protein-1 inhibitor, was also approved as second-line therapy, based on remarkable response rates.

Citations

Citations to this article as recorded by

Analysis of Existing Guidelines and Randomized, Controlled, Clinical Trials for Development of [Guideline of Clinical Trial on Herbal Medicinal Product for Liver Cancer]
Ga-jin Han, Dong-hun Kim, Eun-joo Park, Sin Seong, Sung-su Kim, Jung-tae Leem
The Journal of Internal Korean Medicine.2019; 40(1): 89. CrossRef